JP2003512441A - 極性上皮細胞層を横断するタンパク質の送達 - Google Patents

極性上皮細胞層を横断するタンパク質の送達

Info

Publication number
JP2003512441A
JP2003512441A JP2001532809A JP2001532809A JP2003512441A JP 2003512441 A JP2003512441 A JP 2003512441A JP 2001532809 A JP2001532809 A JP 2001532809A JP 2001532809 A JP2001532809 A JP 2001532809A JP 2003512441 A JP2003512441 A JP 2003512441A
Authority
JP
Japan
Prior art keywords
complex
moiety
activity
bioactive
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001532809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512441A5 (enExample
Inventor
ジェイ． フィッツジェラルド，デビッド
ジェイ． ムルスニー，ランダル
マッキー，ミリアム
ドハーティー，アン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2003512441A publication Critical patent/JP2003512441A/ja
Publication of JP2003512441A5 publication Critical patent/JP2003512441A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001532809A 1999-10-22 2000-10-18 極性上皮細胞層を横断するタンパク質の送達 Withdrawn JP2003512441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
US60/160,923 1999-10-22
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011254351A Division JP2012051939A (ja) 1999-10-22 2011-11-21 極性上皮細胞層を横断するタンパク質の送達

Publications (2)

Publication Number Publication Date
JP2003512441A true JP2003512441A (ja) 2003-04-02
JP2003512441A5 JP2003512441A5 (enExample) 2005-06-30

Family

ID=22579051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001532809A Withdrawn JP2003512441A (ja) 1999-10-22 2000-10-18 極性上皮細胞層を横断するタンパク質の送達
JP2011254351A Pending JP2012051939A (ja) 1999-10-22 2011-11-21 極性上皮細胞層を横断するタンパク質の送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011254351A Pending JP2012051939A (ja) 1999-10-22 2011-11-21 極性上皮細胞層を横断するタンパク質の送達

Country Status (8)

Country Link
US (1) US7824695B1 (enExample)
EP (1) EP1242122B1 (enExample)
JP (2) JP2003512441A (enExample)
AT (1) ATE444081T1 (enExample)
AU (1) AU784657B2 (enExample)
CA (1) CA2389302C (enExample)
DE (1) DE60043070D1 (enExample)
WO (1) WO2001030392A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515808A (ja) * 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
ATE444081T1 (de) 1999-10-22 2009-10-15 Us Gov Health & Human Serv Proteine-abgabe durch polare epithelzellen schichte
CA2631952A1 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
US20090148401A1 (en) * 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
CA2647168A1 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP4082558B1 (en) 2018-03-08 2023-08-23 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
EP0717753B1 (en) * 1993-09-06 1998-12-02 Menarini Ricerche S.p.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
CA2190101A1 (en) 1994-05-13 1995-11-23 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
EP0941334B1 (en) * 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
WO1998042876A1 (en) 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
US6472140B1 (en) 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
ATE444081T1 (de) 1999-10-22 2009-10-15 Us Gov Health & Human Serv Proteine-abgabe durch polare epithelzellen schichte
AU779473B2 (en) 1999-10-22 2005-01-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Disulfide conjugated cell toxins and methods of making and using them
DK1379550T3 (da) 2000-12-21 2009-07-06 Us Gov Health & Human Serv Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515808A (ja) * 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物

Also Published As

Publication number Publication date
JP2012051939A (ja) 2012-03-15
CA2389302A1 (en) 2001-05-03
EP1242122B1 (en) 2009-09-30
ATE444081T1 (de) 2009-10-15
US7824695B1 (en) 2010-11-02
WO2001030392A2 (en) 2001-05-03
AU1339201A (en) 2001-05-08
CA2389302C (en) 2011-03-15
WO2001030392A3 (en) 2002-07-11
EP1242122A2 (en) 2002-09-25
AU784657B2 (en) 2006-05-18
DE60043070D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
JP2012051939A (ja) 極性上皮細胞層を横断するタンパク質の送達
US20200165314A1 (en) Compositions and Methods of Use for Treating Metabolic Disorders
US6423513B1 (en) Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins
US5270199A (en) Human mannose-binding protein
US20030144474A1 (en) T cell receptor fusions and conjugates and methods of use thereof
US7713737B2 (en) Methods and compositions for needleless delivery of macromolecules
JP2003514852A (ja) 炎症反応を阻害する細胞透過性ペプチドおよび使用方法
US20090148401A1 (en) Methods and compositions for needleless delivery of binding partners
US9090691B2 (en) Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
CN117298254A (zh) 用于口服递送生物活性货物的cholix毒素衍生的融合分子
CN101522214A (zh) 用于无针递送颗粒的方法和组合物
AU758576B2 (en) Chemokines with amino-terminal modifications
JP2022118184A (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
US20090305978A1 (en) Methods for increasing the size of animals using needleless delivery constructs
CN114555624A (zh) 抗炎剂
JP2006516253A (ja) 自己免疫疾患を治療および／または予防する方法
CN1997277A (zh) 利用血管内皮细胞生长抑制剂vegi－192a治疗癌症的方法
CN101072584A (zh) 用于无针输送大分子的方法和组合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120210